Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.36 ▼ -0.03
(-8.40%)
MKT CAP: $14.5M • VOL: 79.4K
52W L $0 52W H $2
ROARABLE / RQD
E • 31/100
PIOTROSKI
2 / 9
DYAI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.1M | $3.5M | $2.9M |
| YoY Revenue Growth % | -11.6% | +20.6% | — |
| Gross Profit | $770.5K | $2.3M | — |
| Gross Margin % | 24.9% | 65.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.2M | -$5.9M | -$8.2M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$7.4M | -$5.8M | -$6.8M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.7M | -$4.0M | -$6.7M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$5.7M | -$4.0M | -$6.7M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $4.6M | $6.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $1.2M | $2.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DYAI.